Mara Lecchi

Fondazione IRCCS Istituto Nazionale dei Tumori

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Paolo Verderio

Fondazione IRCCS Istituto Nazionale dei Tumori

Nadia Zaffaroni

Fondazione IRCCS Istituto Nazionale dei Tumori

Silvia Brich

Fondazione IRCCS Istituto Nazionale dei Tumori

Sandro Pasquali

Fondazione IRCCS Istituto Nazionale dei Tumori

Gian Paolo Dagrada

Fondazione IRCCS Istituto Nazionale dei Tumori

Andrew Jenks

Institute of Cancer Research

Paolo G. Casali

Fondazione IRCCS Istituto Nazionale dei Tumori

Anna Maria Frezza

Fondazione IRCCS Istituto Nazionale dei Tumori

Claudia Giani

Fondazione IRCCS Istituto Nazionale dei Tumori

Marta Barisella

Fondazione IRCCS Istituto Nazionale dei Tumori

Cooperative Institutions

Fondazione IRCCS Istituto Nazionale dei Tumori

184

Istituti di Ricovero e Cura a Carattere Scientifico

100

University of Milan

Tumori Foundation

European Institute of Oncology

Vita-Salute San Raffaele University

Memorial Sloan Kettering Cancer Center

University of Turin

Mylan (Switzerland)

University of Genoa

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies

Annals of Oncology (2018)

Maria Silvia Cona Mara Lecchi Silvia Damian Michele Del Vecchio Carolina Cimminiello

Univariate

Univariate analysis

10.1093/annonc/mdy269.109

Cite

Citations (0)

50. Retrospective study of late radiation damages after focal radiotherapy for childhood brain tumors

Physica Medica (2018)

Silvia Meroni Claudia Cavatorta Mara Lecchi Eros Montin C. Oprandi

Neurocognitive

Neuropsychological Assessment

10.1016/j.ejmp.2018.04.060

Cite

Citations (0)

Supplementary Figure 3 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression

Silvia Stacchiotti Silvia Martini Sandro Pasquali Anna Maria Frezza Alessia Beretta

Supplementary Figure 3. Chromosomal architecture of the PDX compared to the clinical sample in chromosomes 7 and 11.

Sirolimus

Epithelioid Hemangioendothelioma

ATF4

10.1158/1078-0432.27754797

Cite

Citations (0)

Supplementary Figure 8 from GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression

Silvia Stacchiotti Silvia Martini Sandro Pasquali Anna Maria Frezza Alessia Beretta

Supplementary Figure 8. GDF-15 silencing did not impair the proliferative potential of EHE cells as well as their migration and invasion and ability to growth in vivo.

Sirolimus

ATF4

Epithelioid Hemangioendothelioma

10.1158/1078-0432.27754779

Cite

Citations (0)

Supplementary Data from ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation

Milena Perrone Claudia Chiodoni Mara Lecchi Laura Botti Barbara Bassani

This file include the Supplementary Table S1A and S1B

10.1158/0008-5472.22432656.v1

Cite

Citations (0)

Table of Contents

ESMO Open (2023)

Deepak Bhamidipati V. Subbiah Luís Castelo-Branco Regent Lee Mariana Brandão

Table (database)

10.1016/s2059-7029(23)00874-8

Cite

Citations (0)

Additional file 4 of Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients

Figshare (2022)

Emanuela Fina Loredana Cleris Matteo Dugo Mara Lecchi Chiara Maura Ciniselli

Additional file 4: Supplementary File S3. File reports results of gene ontology enrichment analysis using genes down-regulated in circulating tumor cells versus solid lesions in MDA-MB-231 xenograft models.

Circulating tumor cell

Breast cancer metastasis

10.6084/m9.figshare.19242454

Cite

Citations (0)

3Rs Principle and Legislative Decrees to Achieve High Standard of Animal Research

Animals (2023)

Paolo Verderio Mara Lecchi Chiara Maura Ciniselli Bjorn Shishmani Giovanni Apolone

Animal experimentation is a vast ecosystem that tries to make different issues such as legislative, ethical and scientific coexist. Research in animal experimentation has made many strides thanks to the 3Rs principle and the attached legislative decrees, but for this very reason, it needs to be evenly implemented both among the countries that have adhered to the decrees and among the team members who design and execute the experimental practice. In this article, we emphasize the importance of the 3Rs principle's application, with a particular focus on the concept of Reduction and related key aspects that can best be handled with the contribution of experts from different fields.

10.3390/ani13020277

Cite

Citations (19)

Potential of the Stromal Matricellular Protein Periostin as a Biomarker to Improve Risk Assessment in Prostate Cancer

International Journal of Molecular Sciences (2022)

Valentina Doldi Mara Lecchi Silva Ljevar Maurizio Colecchia Elisa Campi

Prostate cancer (PCa) ranges from indolent to aggressive tumors that may rapidly progress and metastasize. The switch to aggressive PCa is fostered by reactive stroma infiltrating tumor foci. Therefore, reactive stroma-based biomarkers may potentially improve the early detection of aggressive PCa, ameliorating disease classification. Gene expression profiles of PCa reactive fibroblasts highlighted the up-regulation of genes related to stroma deposition, including periostin and sparc. Here, the potential of periostin as a stromal biomarker has been investigated on PCa prostatectomies by immunohistochemistry. Moreover, circulating levels of periostin and sparc have been assessed in a low-risk PCa patient cohort enrolled in active surveillance (AS) by ELISA. We found that periostin is mainly expressed in the peritumoral stroma of prostatectomies, and its stromal expression correlates with PCa grade and aggressive disease features, such as the cribriform growth. Moreover, stromal periostin staining is associated with a shorter biochemical recurrence-free survival of PCa patients. Interestingly, the integration of periostin and sparc circulating levels into a model based on standard clinico-pathological variables improves its performance in predicting disease reclassification of AS patients. In this study, we provide the first evidence that circulating molecular biomarkers of PCa stroma may refine risk assessment and predict the reclassification of AS patients.

Periostin

Matricellular protein

10.3390/ijms23147987

Cite

Citations (5)

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies

Cancers (2019)

Maria Silvia Cona Mara Lecchi Sara Cresta Silvia Damian Michele Del Vecchio

Predictive biomarkers of response to immune-checkpoint inhibitors (ICIs) are an urgent clinical need. The aim of this study is to identify manageable parameters to use in clinical practice to select patients with higher probability of response to ICIs. Two-hundred-and-seventy-one consecutive metastatic solid tumor patients, treated from 2013 until 2017 with anti- Programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) ICIs, were evaluated for baseline lactate dehydrogenase (LDH) serum level, performance status (PS), age, neutrophil-lymphocyte ratio, type of immunotherapy, number of metastatic sites, histology, and sex. A training and validation set were used to build and test models, respectively. The variables' effects were assessed through odds ratio estimates (OR) and area under the receive operating characteristic curves (AUC), from univariate and multivariate logistic regression models. A final multivariate model with LDH, age and PS showed significant ORs and an AUC of 0.771. Results were statistically validated and used to devise an Excel algorithm to calculate the patient's response probabilities. We implemented an interactive Excel algorithm based on three variables (baseline LDH serum level, age and PS) which is able to provide a higher performance in response prediction to ICIs compared with LDH alone. This tool could be used in a real-life setting to identify ICIs in responding patients.

Univariate

Univariate analysis

10.3390/cancers11020223

Cite

Citations (22)